Literature DB >> 26282273

Cannabinoids and Epilepsy.

Evan C Rosenberg1, Richard W Tsien1, Benjamin J Whalley2, Orrin Devinsky3.   

Abstract

Cannabis has been used for centuries to treat seizures. Recent anecdotal reports, accumulating animal model data, and mechanistic insights have raised interest in cannabis-based antiepileptic therapies. In this study, we review current understanding of the endocannabinoid system, characterize the pro- and anticonvulsive effects of cannabinoids [e.g., Δ9-tetrahydrocannabinol and cannabidiol (CBD)], and highlight scientific evidence from pre-clinical and clinical trials of cannabinoids in epilepsy. These studies suggest that CBD avoids the psychoactive effects of the endocannabinoid system to provide a well-tolerated, promising therapeutic for the treatment of seizures, while whole-plant cannabis can both contribute to and reduce seizures. Finally, we discuss results from a new multicenter, open-label study using CBD in a population with treatment-resistant epilepsy. In all, we seek to evaluate our current understanding of cannabinoids in epilepsy and guide future basic science and clinical studies.

Entities:  

Keywords:  Epilepsy; THC; cannabidiol; cannabinoids; cannabis; seizures

Mesh:

Substances:

Year:  2015        PMID: 26282273      PMCID: PMC4604191          DOI: 10.1007/s13311-015-0375-5

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  320 in total

1.  Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism.

Authors:  M P Caulfield; D A Brown
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

2.  Molecular composition of the endocannabinoid system at glutamatergic synapses.

Authors:  István Katona; Gabriella M Urbán; Matthew Wallace; Catherine Ledent; Kwang-Mook Jung; Daniele Piomelli; Ken Mackie; Tamás F Freund
Journal:  J Neurosci       Date:  2006-05-24       Impact factor: 6.167

Review 3.  Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress.

Authors:  George W Booz
Journal:  Free Radic Biol Med       Date:  2011-01-14       Impact factor: 7.376

4.  Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells.

Authors:  Alison J Drysdale; Duncan Ryan; Roger G Pertwee; Bettina Platt
Journal:  Neuropharmacology       Date:  2005-12-28       Impact factor: 5.250

5.  Protein kinase-dependent phosphorylation and cannabinoid receptor modulation of potassium A current (IA) in cultured rat hippocampal neurons.

Authors:  J Mu; S Y Zhuang; R E Hampson; S A Deadwyler
Journal:  Pflugers Arch       Date:  2000-03       Impact factor: 3.657

6.  Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice.

Authors:  D M Lambert; S Vandevoorde; G Diependaele; S J Govaerts; A R Robert
Journal:  Epilepsia       Date:  2001-03       Impact factor: 5.864

7.  Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut Syndrome. The Group for the Evaluation of Cinromide in the Lennox-Gastaut Syndrome.

Authors: 
Journal:  Epilepsia       Date:  1989 Jul-Aug       Impact factor: 5.864

8.  The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice.

Authors:  Hamed Shafaroodi; Morteza Samini; Leila Moezi; Houman Homayoun; Hamed Sadeghipour; Sina Tavakoli; Amir Reza Hajrasouliha; Ahmad Reza Dehpour
Journal:  Neuropharmacology       Date:  2004-09       Impact factor: 5.250

9.  Postsynaptic spike firing reduces synaptic GABAA responses in hippocampal pyramidal cells.

Authors:  T A Pitler; B E Alger
Journal:  J Neurosci       Date:  1992-10       Impact factor: 6.167

10.  Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor.

Authors:  Gregory I Liou; John A Auchampach; Cecilia J Hillard; Gu Zhu; Bilal Yousufzai; Salman Mian; Sohail Khan; Yousuf Khalifa
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-07-18       Impact factor: 4.799

View more
  48 in total

Review 1.  Control of excessive neural circuit excitability and prevention of epileptic seizures by endocannabinoid signaling.

Authors:  Yuki Sugaya; Masanobu Kano
Journal:  Cell Mol Life Sci       Date:  2018-05-08       Impact factor: 9.261

2.  Cannabidiol and Epilepsy: Sifting, Winnowing and Buzz.

Authors:  Barry E Gidal
Journal:  Epilepsy Curr       Date:  2016 Jul-Aug       Impact factor: 7.500

3.  Characterization of structurally novel G protein biased CB1 agonists: Implications for drug development.

Authors:  Benjamin M Ford; Lirit N Franks; Sherrica Tai; William E Fantegrossi; Edward L Stahl; Michael D Berquist; Christian V Cabanlong; Catheryn D Wilson; Narsimha R Penthala; Peter A Crooks; Paul L Prather
Journal:  Pharmacol Res       Date:  2017-08-23       Impact factor: 7.658

Review 4.  Treatment Strategies for Dravet Syndrome.

Authors:  Kelly G Knupp; Elaine C Wirrell
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

5.  Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models.

Authors:  Paula Morales; Patricia H Reggio
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.

Authors:  Victoria Golub; D Samba Reddy
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Prospects of Cannabidiol for Easing Status Epilepticus-Induced Epileptogenesis and Related Comorbidities.

Authors:  Dinesh Upadhya; Olagide W Castro; Raghavendra Upadhya; Ashok K Shetty
Journal:  Mol Neurobiol       Date:  2018-01-25       Impact factor: 5.590

Review 8.  Development of cannabidiol as a treatment for severe childhood epilepsies.

Authors:  Claire M Williams; Gary J Stephens
Journal:  Br J Pharmacol       Date:  2020-10-27       Impact factor: 8.739

Review 9.  The pharmacokinetics and the pharmacodynamics of cannabinoids.

Authors:  Catherine J Lucas; Peter Galettis; Jennifer Schneider
Journal:  Br J Clin Pharmacol       Date:  2018-08-07       Impact factor: 4.335

Review 10.  Managing Antiepileptic Medication in Dialysis Patients.

Authors:  Karla Alejandra Mora Rodríguez; Selim R Benbadis
Journal:  Curr Treat Options Neurol       Date:  2018-09-27       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.